SVCM
OVID icon

Saturn V Capital Management’s Ovid Therapeutics OVID Stock Holding History

Saturn V Capital Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.25M Buy
4,166,666
+1,666,666
+67% +$2.98M 1.68% 17
2025
Q4 		$4.08M Buy
+2,500,000
New +$3.85M 0.75% 19

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Saturn V Capital Management's OVID Position: Q1 2026 in Review

Saturn V Capital Management increased its Ovid Therapeutics (OVID) stake by 67% in Q1 2026, buying an estimated $2.98M and bringing the position to 4,166,666 shares worth $9.25M. The position accounts for 1.68% of the portfolio, ranked #17.

Saturn V Capital Management first reported a position in OVID in Q4 2025 and has held it in 2 quarters since. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • Saturn V Capital Management held 4,166,666 shares of Ovid Therapeutics worth $9.25M as of Q1 2026.
  • Saturn V Capital Management bought 1,666,666 Ovid Therapeutics shares in Q1 2026, an estimated $2.98M.
  • Ovid Therapeutics made up 1.68% of Saturn V Capital Management's portfolio in Q1 2026, its #17 holding.
  • Saturn V Capital Management first reported a position in Ovid Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Saturn V Capital Management's 13F filing for Q1 2026, filed 15 May 2026.